---
created: 2025-04-13
updated: 2025-04-13T10:52
id: Ag,:S5%%u~
specialty: cardio
specialty_id: 63
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/b&b::05-cardio::04-arrhythmias::06-antiarrhythmic-drugs
  - "source/ak-step1-v11:": 
  - theme/firstaid::07-cardiovascular::05-pharm::12-16-antiarrythmics::12-class-1-sodium-channel-blockers
  - "source/ak-step1-v11:": 
  - source/ome-banner::basic-science::09-cardiac::25-arrhythmias
  - "source/ak-step1-v11:": 
  - theme/physeo::09-pharm::10-cardiac::17-class-ia,-ib,-and-ic-antiarrhythmics
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::02-cardio-&-renal::04-antiarrhythmics::01-class-i-a-c
  - source/ak-step1-v11::^other::^highyield::2-relativelyhighyield
  - source/ak-step1-v11::^systems::cardio::pharmacology
  - "source/ak-step2-v11:": 
  - theme/b&b::01-cardiology::pharm::cvs-pharm-1"
type: flashcard
---

# Question
What effect do class IC antiarrhythmics have on the effective refractory period in the AV node and accessory bypass tracts?    **Significant prolongation of ERP**

---

# Answer
